Devizes Community Hospital

Abstract Brush seals consist of a static ring of densely packed, flexible, fine wire bristles that provide resistance to the flow. Pressure relieving brush seals can be employed to overcome issues such as hysteresis that affect seal durability by reducing friction between the bristle pack and back plate surface. The impact of such designs on the fluid dynamic behavior of brush seals was studied following a concomitant methodology that exploited the benefits of both engine representative and large-scale testing facilities. Leakage data were fitted using a porous medium model found in the literature to quantify viscous and inertial resistance coefficients. Shaft rotation was shown to cause a reduction in seal leakage and an increase in static pressure on the back plate surface. The pressure relieving back plates also resulted in increased static pressures at this location, causing a reduction in flow resistance that increased leakage through the porous bristle pack. Interrogation of the large-scale inter-bristle pressure field for the two back plate designs revealed the distributions of axial pressure diverged toward the rear of the bristle pack. The detail gathered using the large-scale study has been shown to be representative; hence, the insight is generically applicable to brush seals.

A workshop held at the 18th Annual Conference of the Pharmaceutical Contract Management Group in Krakow on 9 September 2022 asked over 200 delegates what the clinical trial landscape would look like in 2050. Issues considered included who will be running the pharmaceutical industry in 2050; how 'health chips', wearables and diagnostics will impact on finding the right patients to study; how will artificial intelligence be designing and controlling clinical trials; and what will the role of the Clinical Research Associate, the critical observer, documenter and conductor of a clinical trial need to look like by 2050. The consensus was that, by 2050, if you are working in clinical trials, you will be a data scientist. We can expect to see an increasing role of new technologies and a new three-phase registration model for novel therapies. The first phase will involve an aspect of quality evaluation and biological proof-of-concept probably involving more preclinical modelling and engineered human cell lines and fewer animal studies than currently used. Once registered, new products will enter a period of adaptive clinical development (delivered as a single study) intended to establish safety. This phase will most likely take around 1-2 years and explore tailored options for administration. Investigations will most likely be conducted in patients, possibly in a 'patient-in-a-box' setting (hospital or healthcare centre, virtual or microsite). On completion of safety licencing, drugs will begin an assessment of efficacy in partnership with those responsible for reimbursement - testing will be performed in patients, possibly where individual patient involvement in safety testing will offer some reimbursement deal for future treatment. Change is coming, though its precise form will likely depend on the creativity and vision of sponsors, regulators and payers.

Abstract Gas has been found in Mesozoic reservoirs in the Weald Basin, particularly along the northern margin. Most of the gas is dry, with a high methane content and often associated nitrogen. Isotopic evidence indicates that the gas is from a thermogenically mature marine source. Although there is evidence of some shallow, biogenic gas, only the lowermost Lias is projected to have reached the thermogenic gas window before Tertiary uplift. Estimated maturities from isotopic data from the main gas accumulations indicate significantly greater levels than those projected for Liassic shales: thus, the gas is thought to have originated from Paleozoic rocks. Data on the distribution of Paleozoic rocks subcropping the Variscan unconformity is limited. However, available data suggest that their distribution owes more to Acadian erosion than to Variscan. It is thought that the Upper Devonian and Lower Carboniferous transgressed over a thick, folded Tremadocian shale sequence in the west, and over folded Silurian and Lower–Middle Devonian rocks in the central Weald. There is some evidence for the presence of isolated late Carboniferous or early Permian clastics but no significant coals have been encountered to date. Regional source studies suggest that the only Paleozoic rocks with potential are post-Acadian-aged Devonian shales.

In the mid — 1980’s, Microsoft introduced the first version of a Windows GUI style database to complement their standard Office products. This product was to form a major part of what is now known as the Office product range.

Visual Basic is Microsoft’s underlying development language for all Office components; with this language you can manipulate not only the product you are currently using but also any Office object or ActiveX component. While the language is reasonably easy to use, the syntax and methods require more time to fully understand.KeywordsExchange RateEvent PropertyNumeric ExpressionFocus EventDesign ViewThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

In recent years water pool temperature has been the subject of Intensive debate. This paper revisits some of the issues and reviews some of the scant research carried out into the response of the fetus to hyperthermia. The safety of hot water immersion during labour has recently been questioned following problems with two babies born in Bristol in 1.993. Neither baby was delivered in water, but both mothers remained immersed for some hours during labour, and it was suggested that fetal hyperthermia might have been a factor. The ensuing debate has been hampered by a lack of satisfactory research into the risks and benefits of labour and delivery in water. This study is intended to examine the limited evidence available on the causes and effects of fetal hyperthermia.

Teicoplanin was used in three hospitals over 6 years in 112 cases of bone or joint infection and the results were reviewed retrospectively. Teicoplanin was used at a dose of 400 mg/day, after a 3-day loading regimen, in combination with other agents, usually netilmicin at the beginning of the treatment. Most infections were chronic (mean duration = 20.9 months) and had failed previous antibiotic or surgical treatment. Gram-positive organisms were isolated in 120/137 identified strains (64 methicillin-resistant Staphylococcus aureus or coagulase négative Staphylococci) and all were susceptible to teicoplanin except one (intermediate for NCCLS norms). Median of follow-up was 17.3 months. The final outcome was clinical cure in 89/98 evaluable cases (91%). There were one improvement, four failures and four recurrences. Adverse events occurred in 11 patients (10%) but did not require any change in treatment. Despite the limitations of a retrospective study, teicoplanin appeared to be effective, well tolerated and easy to use with only one daily injection.RéSUMé: Une étude rétrospective, non comparative, de l'utilisation de la teicoplanine sur 112 cas d'infection ostéo-articulaire pendant 6 ans dans trois hopitaux Français est rapportée. La teicoplanine a été utilisée à la dose de 400 mg/j, après une dose de charge de 3 jours, en association avec d'autres antibiotiques (le plus souvent la netilmycine en début de traitement). Ces infections étaient chroniques (durée d'évolution moyenne de 20,9 mois) et avaient déjà fait l'objet de traitements antérieurs médicaux ou chirurgicaux. Cent vingt cocci gram positif étaient retrouvés sur les 137 souches isolées (64Staphylococus Aureus ou Epidermidis résistant à la methicillin) et tous sauf une (intermédiaire selon les normes NCCLS) étaient sensibles à la teicoplanine. Après une durée de suivi moyenne à 17,3 mois, 89 des 98 cas evaluables (91 %) étaient considérés comme guéris. On retrouvait également 1 amélioration, 4 échecs et 4 récurrences. Un effet secondaire a été noté chez 11 patients (10 %) mais n'a jamais necessité un changement de traitement témoignant ainsi de la bonne tolérance observée avec cette molécule facile à utiliser gràce à une seule injection par jour.